Autologous Tumour-Infiltrating Lymphocytes

6 trials 2 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

3 Completed trials

3 Sponsors

8 Countries

Phase II

Phase II: 6

Oversight events:

5 temporary halts 1 unexpected event across 1 trial

View oversight register →

Indications tested

Germ cell cancer 1 Squamous cell carcinoma of head and neck 1 Non-small cell lung cancer 1

Sponsors using this IMP

Iovance Biotherapeutics Inc. 3 Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL 2 Vall D Hebron Institute Of Oncology 1

All trials

6 total

A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study Pending

2025-522427-10-00 Phase II 1 country Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be… Recruiting

2024-510778-26-00 Phase II 6 countries Iovance Biotherapeutics Inc.
Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after… Recruiting

2023-506400-99-00 Phase II 3 countries Vall D Hebron Institute Of Oncology
A phase 2, Multicenter Study of TILs Treatment in Advanced Tumors with Alterations in the SWI/SNF Complex: the TILTS Study Ended

2023-504632-17-00 Phase II 1 country Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBELL
A clinical study to investigate if the investigational products, called LN-144 and LN-145 (also known as Tumour Infiltrating Lymphocytes), a… Ended

2024-510779-39-00 Phase II 3 countries Iovance Biotherapeutics Inc.
A study to find out if an investigational product, called LN-145 (also called tumor infiltrating lymphocytes) is an effective and safe treat… Ended

2024-510634-41-00 Phase II 5 countries Iovance Biotherapeutics Inc.

Showing 1–6 of 6 trials

← All drugs A–Z